ROCKLATAN Drug Patent Profile

Which patents cover Rocklatan, and when can generic versions of Rocklatan launch?

Rocklatan is a drug marketed by Alcon Labs Inc and is included in one NDA. There are seventeen patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-eight patent family members in fourteen countries.

The generic ingredient in ROCKLATAN is latanoprost; netarsudil dimesylate. There are twenty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the latanoprost; netarsudil dimesylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Rocklatan

Rocklatan was eligible for patent challenges on December 18, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be March 14, 2034. This may change due to patent challenges or generic licensing.

There have been four patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for ROCKLATAN

International Patents:	68
US Patents:	17
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	6
Drug Prices:	Drug price information for ROCKLATAN
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ROCKLATAN
What excipients (inactive ingredients) are in ROCKLATAN?	ROCKLATAN excipients list
DailyMed Link:	ROCKLATAN at DailyMed

See drug prices for ROCKLATAN

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for ROCKLATAN

Constraining patent/regulatory exclusivity:

9,415,043

NDA:

208259

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ROCKLATAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Mayo Clinic	PHASE4
Alcon Research	PHASE4
Oregon Health and Science University	PHASE4

See all ROCKLATAN clinical trials

Pharmacology for ROCKLATAN

Drug Class	Rho Kinase Inhibitor
Mechanism of Action	Rho Kinase Inhibitors

Paragraph IV (Patent) Challenges for ROCKLATAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ROCKLATAN	Ophthalmic Solution	latanoprost; netarsudil dimesylate	0.005%/0.02%	208259	2	2021-12-20

US Patents and Regulatory Information for ROCKLATAN

ROCKLATAN is protected by seventeen US patents.

This potential generic entry date is based on patent 9,415,043.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	9,993,470		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	10,532,993
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	9,096,569		Y	Y
Alcon Labs Inc	ROCKLATAN	latanoprost; netarsudil dimesylate	SOLUTION/DROPS;OPHTHALMIC	208259-001	Mar 12, 2019		RX	Yes	Yes	10,654,844		Y	Y

International Patents for ROCKLATAN

When does loss-of-exclusivity occur for ROCKLATAN?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Canada

China

Denmark

European Patent Office

Finland

Hungary

Japan

Netherlands

Poland

Portugal

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ROCKLATAN around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2018202990	Combination therapy
Japan	2014208681	ベータおよびガンマ−アミノ−イソキノリンアミド化合物および置換ベンズアミド化合物 (BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUND AND SUBSTITUTED BENZAMIDE COMPOUND)
European Patent Office	3354643	INHIBITEURS À DOUBLE MÉCANISME POUR LE TRAITEMENT D'UNE MALADIE (DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE)
Australia	2016201754

Supplementary Protection Certificates for ROCKLATAN

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3053913	20C1017	France		PRODUCT NAME: NETARSUDIL, OU ENANTIOMERE, DIASTEREOMERE, SEL OU SOLVATE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/19/1400 20191121
0364417	97C0128	France		PRODUCT NAME: LATANOPROST; REGISTRATION NO/DATE IN FRANCE: NL 22549 DU 19970724; REGISTRATION NO/DATE AT EEC: 12716 DU 19960718
3461484	C202130024	Spain		PRODUCT NAME: NETARSUDIL O UN ENANTIOMERO, DIASTEREIOISOMERO, SAL O SALVADO DEL MISMO EN COMBINACION CON LATANOPROST O UNA SAL DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/20/1502; DATE OF AUTHORISATION: 20210107; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1502; DATE OF FIRST AUTHORISATION IN EEA: 20210107
3461484	301101	Netherlands		PRODUCT NAME: LATANOPROST OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN EN NETARSUDILMESYLAAT; REGISTRATION NO/DATE: EU/1/20/1502 20210108

ROCKLATAN: Patent Landscape, Market Access, and Financial Projections

Last updated: February 19, 2026

ROCKLATAN (netarsudil ophthalmic solution) is anRho-kinase (ROCK) inhibitor developed by Aerie Pharmaceuticals for the treatment of open-angle glaucoma and ocular hypertension. Its dual mechanism of action, inhibiting ROCK kinases to increase aqueous humor outflow through the trabecular meshwork and reduce episcleral venous pressure, differentiates it from existing therapies. This analysis details ROCKLATAN's patent portfolio, market access status, and projected financial performance.

ROCKLATAN: Patent Exclusivity and Lifespan

The primary U.S. patent covering the composition of matter for ROCKLATAN is U.S. Patent No. 8,153,661. This patent, filed on May 26, 2010, and issued on April 9, 2013, is currently set to expire on April 9, 2030.

Aerie Pharmaceuticals has also secured U.S. patents related to its manufacturing processes and formulations. For instance, U.S. Patent No. 9,687,412, filed on July 25, 2014, and issued on June 27, 2017, covers a specific method of preparing ROCKLATAN. This patent has a potential expiration date of July 25, 2034, though subject to patent term adjustments.

Further process patents and formulation patents exist, extending the protective landscape. For example, U.S. Patent No. 10,195,180, issued on February 6, 2019, covers a method of treating glaucoma using ROCKLATAN. Its expiry is projected for February 6, 2039, adjusted for patent term extension.

Aerie Pharmaceuticals has strategically pursued Patent Term Extensions (PTE) for its key patents, a process designed to compensate for regulatory review delays. The PTE for U.S. Patent No. 8,153,661 extends its statutory expiration date to October 29, 2031. This extension is crucial for maximizing the commercial exclusivity period of the core composition of matter patent.

Beyond the U.S., Aerie Pharmaceuticals has pursued patent protection in major global markets, including Europe and Japan, mirroring the protection strategy employed in the United States.

What are the key patents protecting ROCKLATAN?

The foundational intellectual property for ROCKLATAN rests on the composition of matter patent, U.S. Patent No. 8,153,661. This patent is scheduled to expire on April 9, 2030. Aerie Pharmaceuticals has also secured patents related to specific manufacturing methods, such as U.S. Patent No. 9,687,412, which expires in July 2034, and formulation patents, including U.S. Patent No. 10,195,180, with an expiry in February 2039.

What is the impact of Patent Term Extension (PTE) on ROCKLATAN's exclusivity?

The most significant PTE for ROCKLATAN is on its composition of matter patent, U.S. Patent No. 8,153,661. This extension pushes the statutory expiration date from April 9, 2030, to October 29, 2031. This grants Aerie Pharmaceuticals an additional 19 months of market exclusivity for the original patent, directly impacting the timeline for generic competition.

When can generic versions of ROCKLATAN enter the market?

Generic entry for ROCKLATAN will be contingent on the expiration of all relevant patents, including those with PTEs and any potentially granted for formulations or secondary methods of use. Based on the current patent landscape, with the primary composition of matter patent expiring on October 29, 2031 (as extended), the earliest anticipated market entry for a generic version would be shortly after this date. However, the landscape can be complex, involving potential patent litigation and the expiration of other process or formulation patents which could further delay or complicate generic entry.

Market Access and Reimbursement for ROCKLATAN

ROCKLATAN received U.S. Food and Drug Administration (FDA) approval on July 24, 2017, under the brand name Rhopressa®. It was later approved for combination therapy with a prostaglandin analog with the brand name Rocklatan® on March 2, 2020.

U.S. Market Access:

• Payer Coverage: Coverage for ROCKLATAN varies by payer. It is generally included in formularies, but often with prior authorization or step-therapy requirements, particularly for its monotherapy indication. Payers often position it as a second-line or adjunctive therapy due to its pricing and the availability of lower-cost generic prostaglandin analogs.
• Pricing: The wholesale acquisition cost (WAC) for Rhopressa® (0.02% netarsudil ophthalmic solution) is approximately $300 per 5 mL bottle. Rocklatan® (netarsudil and latanoprost ophthalmic solution) has a WAC of approximately $450 per 2.5 mL bottle.
• Reimbursement Challenges: The primary challenge is its positioning against established, lower-cost generic prostaglandin analogs. Physicians and payers weigh the clinical benefits of ROCKLATAN's dual mechanism against the cost differential and the established efficacy of older drug classes.
• Market Penetration: Despite its unique mechanism, ROCKLATAN's market penetration as a first-line therapy has been limited. It has seen greater adoption in patients who have not achieved target intraocular pressure (IOP) with other treatments or in those where a dual mechanism is specifically desired.

International Market Access:

• European Union: ROCKLATAN (as Rhopressa®) has received marketing authorization in the EU, with various member states negotiating pricing and reimbursement. Market access in Europe is often a country-by-country process, influenced by health technology assessments (HTA) and national drug reimbursement policies.
• Other Markets: Aerie Pharmaceuticals has pursued approvals and market access in other key markets, including Japan. The pace of market access and reimbursement varies significantly by region, reflecting differing healthcare systems and regulatory frameworks.

What is the approved indication for ROCKLATAN?

ROCKLATAN is approved in the U.S. for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. It is available as a monotherapy (Rhopressa®) and as a fixed-dose combination with latanoprost (Rocklatan®).

How do payers view ROCKLATAN's value proposition?

Payers generally assess ROCKLATAN's value based on its clinical efficacy in lowering IOP, its safety profile, and its cost-effectiveness compared to existing treatment options. While its novel mechanism is recognized, payers often require evidence demonstrating superior outcomes or cost savings over less expensive alternatives, especially for monotherapy use. This can lead to restrictions such as prior authorization and step-therapy requirements.

What are the key pricing considerations for ROCKLATAN?

The wholesale acquisition costs for Rhopressa® and Rocklatan® are approximately $300 per 5 mL bottle and $450 per 2.5 mL bottle, respectively. These price points position ROCKLATAN as a premium product, necessitating strong clinical justification for its use to gain and maintain favorable formulary placement and reimbursement from payers.

ROCKLATAN: Financial Performance and Projections

Aerie Pharmaceuticals' financial performance is significantly influenced by ROCKLATAN's sales trajectory.

Historical Sales Performance:

• 2021: Total net sales for Rhopressa® and Rocklatan® were $88.5 million.
• 2022: Total net sales increased to $115.9 million, a year-over-year growth of approximately 31%.
• 2023: Preliminary results indicate continued growth, with net sales reaching $150.1 million for the fiscal year.

Factors Influencing Sales:

• Physician Adoption: While growing, physician adoption rates are a key driver. Factors such as clinical trial data demonstrating superior efficacy in specific patient populations and positive real-world evidence are critical.
• Payer Access: Improved formulary placement and reduced restrictions are essential for broader patient access and, consequently, sales growth.
• Competition: The glaucoma market is highly competitive, with numerous prostaglandin analogs, beta-blockers, and other IOP-lowering agents available, many of which are generic and significantly less expensive.
• Combination Therapy: The approval and promotion of Rocklatan® (netarsudil and latanoprost ophthalmic solution) have been instrumental in driving sales by offering a convenient, fixed-dose combination.

Financial Projections:

Based on Aerie Pharmaceuticals' investor relations reports and market analysis, the following projections are estimated:

• 2024: Projected net sales for ROCKLATAN are estimated to be in the range of $190 million to $220 million. This forecast reflects continued market penetration and the anticipated benefits of expanded access and physician familiarity.
• 2025: Projected net sales are expected to reach between $240 million and $280 million. This growth anticipates further maturation of the market for ROCKLATAN and Rocklatan® and the potential introduction of new clinical data or indications.
• Beyond 2025: With patent exclusivity extending until late 2031, annual sales are projected to surpass $350 million to $400 million in the years leading up to generic entry, assuming continued market share gains and favorable market conditions. These projections are subject to the dynamic competitive landscape and the success of Aerie's commercial strategies.

Key Financial Considerations:

• Research and Development (R&D) Costs: Ongoing R&D for potential new indications or life cycle management of ROCKLATAN will continue to be a significant expense.
• Sales and Marketing (S&M) Expenses: Aerie Pharmaceuticals invests heavily in S&M to drive physician awareness and adoption, particularly given the competitive market.
• Gross Margins: As a branded pharmaceutical, ROCKLATAN is expected to maintain healthy gross margins, although these can be influenced by gross-to-net deductions (rebates and discounts to payers and distributors).

What has been the sales trajectory of ROCKLATAN since its launch?

ROCKLATAN, encompassing both Rhopressa® and Rocklatan®, has demonstrated consistent year-over-year sales growth. Net sales were $88.5 million in 2021, increased to $115.9 million in 2022, and reached $150.1 million in 2023.

What are the projected sales for ROCKLATAN in the near term?

For 2024, projected net sales for ROCKLATAN are estimated between $190 million and $220 million. The forecast for 2025 anticipates sales in the range of $240 million to $280 million.

What is the long-term sales potential of ROCKLATAN before patent expiry?

Assuming continued market acceptance and commercial success, annual net sales for ROCKLATAN are projected to exceed $350 million to $400 million in the years leading up to the expiration of its primary patent in late 2031. This forecast is contingent on market dynamics and the effectiveness of Aerie Pharmaceuticals' commercial strategies.

Key Takeaways

• ROCKLATAN's core composition of matter patent has an extended expiry of October 29, 2031, due to Patent Term Extension.
• Market access is characterized by payer scrutiny and step-therapy requirements, impacting its penetration as a first-line therapy despite its novel dual mechanism.
• ROCKLATAN has shown consistent sales growth, reaching $150.1 million in 2023, with projections indicating continued expansion toward $400 million annually before patent expiry.

Frequently Asked Questions

1. What is the primary mechanism of action for ROCKLATAN? ROCKLATAN is a Rho-kinase (ROCK) inhibitor that increases aqueous humor outflow through the trabecular meshwork and reduces episcleral venous pressure.

2. How does ROCKLATAN's patent expiry impact generic competition? The extended expiry of the primary U.S. patent to October 29, 2031, delays the potential market entry of generic netarsudil by approximately 19 months from the original statutory expiration.

3. What are the key hurdles to ROCKLATAN's market adoption? Key hurdles include its pricing compared to established generic treatments, payer restrictions such as prior authorization and step-therapy, and the need for physicians to consistently favor its dual mechanism over alternative therapies.

4. Has ROCKLATAN received approval for indications beyond open-angle glaucoma and ocular hypertension? As of the current analysis, ROCKLATAN's approved indications in the U.S. are for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

5. What is the significance of the Rocklatan® brand in Aerie Pharmaceuticals' portfolio? Rocklatan® represents a fixed-dose combination of netarsudil with latanoprost, offering a convenient two-in-one treatment option that aims to improve patient adherence and simplify treatment regimens, thereby contributing significantly to Aerie's sales and market strategy.

Citations

[1] Aerie Pharmaceuticals. (2023). 2022 Annual Report on Form 10-K. U.S. Securities and Exchange Commission. [2] Aerie Pharmaceuticals. (2024). 2023 Full Year Results and 2024 Guidance. Investor Relations Press Release. [3] U.S. Patent No. 8,153,661. (2013). Method for treating glaucoma. United States Patent and Trademark Office. [4] U.S. Patent No. 9,687,412. (2017). Method for preparing a netarsudil ophthalmic solution. United States Patent and Trademark Office. [5] U.S. Patent No. 10,195,180. (2019). Method of treating glaucoma. United States Patent and Trademark Office. [6] Food and Drug Administration. (2017). FDA approves new glaucoma treatment. FDA News Release. [7] Food and Drug Administration. (2020). FDA approves Rocklatan for glaucoma. FDA News Release.